1. Home
  2. COEP vs SCNX Comparison

COEP vs SCNX Comparison

Compare COEP & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COEP
  • SCNX
  • Stock Information
  • Founded
  • COEP 2017
  • SCNX 2010
  • Country
  • COEP United States
  • SCNX United States
  • Employees
  • COEP N/A
  • SCNX N/A
  • Industry
  • COEP Biotechnology: Biological Products (No Diagnostic Substances)
  • SCNX Other Pharmaceuticals
  • Sector
  • COEP Health Care
  • SCNX Health Care
  • Exchange
  • COEP Nasdaq
  • SCNX Nasdaq
  • Market Cap
  • COEP 32.4M
  • SCNX 33.6M
  • IPO Year
  • COEP N/A
  • SCNX 2020
  • Fundamental
  • Price
  • COEP $12.45
  • SCNX $3.15
  • Analyst Decision
  • COEP
  • SCNX
  • Analyst Count
  • COEP 0
  • SCNX 0
  • Target Price
  • COEP N/A
  • SCNX N/A
  • AVG Volume (30 Days)
  • COEP 111.8K
  • SCNX 10.8K
  • Earning Date
  • COEP 03-25-2025
  • SCNX 02-25-2025
  • Dividend Yield
  • COEP N/A
  • SCNX N/A
  • EPS Growth
  • COEP N/A
  • SCNX N/A
  • EPS
  • COEP N/A
  • SCNX 3.55
  • Revenue
  • COEP N/A
  • SCNX N/A
  • Revenue This Year
  • COEP N/A
  • SCNX $1,085.75
  • Revenue Next Year
  • COEP N/A
  • SCNX N/A
  • P/E Ratio
  • COEP N/A
  • SCNX $1.37
  • Revenue Growth
  • COEP N/A
  • SCNX 166.67
  • 52 Week Low
  • COEP $2.31
  • SCNX $3.01
  • 52 Week High
  • COEP $13.70
  • SCNX $44.56
  • Technical
  • Relative Strength Index (RSI)
  • COEP 63.21
  • SCNX N/A
  • Support Level
  • COEP $8.65
  • SCNX N/A
  • Resistance Level
  • COEP $12.95
  • SCNX N/A
  • Average True Range (ATR)
  • COEP 1.64
  • SCNX 0.00
  • MACD
  • COEP -0.16
  • SCNX 0.00
  • Stochastic Oscillator
  • COEP 75.25
  • SCNX 0.00

About COEP Coeptis Therapeutics Holdings Inc.

Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.

About SCNX Scienture Holdings Inc. Common Stock

Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.

Share on Social Networks: